LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.55 EUR | -1.51% |
|
-0.73% | +35.55% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.63B | ||||||
| 700B | ||||||
| 358B | ||||||
| 330B | ||||||
| 287B | ||||||
| 236B |
